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FAP Familial Adenomatous Polyposis 
FBC Full blood count 
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FOLFOX 5-fluorouracil plus oxaliplatin  
FSIG Flexible sigmoidoscopy 
GP General Practitioner 
HNPCC Hereditary Non-Polyposis Colorectal Cancer 
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IAP Ileoanal pouch 
IBS Irritable bowel syndrome 
IRA Ileorectal anastomosis 
LR Local relapse 
MDT Multidisciplinary team 
MMR Mismatch repair 
MRI Magnetic resonance imaging 
NICE National Institute for Health and Clinical Excellence 
OGD Oesophagogastroduodenoscopy 
PR Per rectal 
TME Total mesorectal excision 
TNM Tumour Node Metastases 
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1.1 Introduction 
This paper sets out a series of descriptive conceptual models of colorectal cancer and its 
detection, diagnosis, treatment and follow-up. The paper is based on an update of the work 
reported in Trueman et al
1
 and is intended to be useful for health economic modellers and 
other researchers working in the area of colorectal cancer evaluation. In particular, it is 
intended that this paper should provide a consistent conceptual basis for the development of 
health economic models of colorectal cancer services and technologies in the future. The 
paper is set out as follows. Section 1.2 details the methods used in the development of these 
conceptual models. Sections 1.3 presents the key disease-specific factors associated with 
colorectal cancer. Section 1.4 presents a series of problem-oriented conceptual models of 
colorectal cancer service pathways.  
 
1.2 Methods for conceptual model development 
The conceptual models presented within this chapter have been informed by guidelines for the 
management of colorectal cancer,
2-6
 NICE Technology Appraisal Guidance documents and 
associated technology assessment reports,
7-17
 other relevant literature (particularly Phillips et 
al
18
) together with considerable clinical input and scrutiny (see Acknowledgements). Whilst 
the conceptual models focus on colorectal cancer, the boundary around the disease and 
service pathways models is broader, including individuals who interact with the colorectal 
cancer service do not yet have and may never develop colorectal cancer (e.g. screen-eligible 
general population, individuals under surveillance for colitis). In line with the methods 
detailed by Tappenden et al,
19
 two conceptual model views are presented here: 
(1) A problem-oriented disease logic model which sets out key disease-related events and 
processes associated with colorectal cancer (Section 1.3). 
(2) A problem-oriented service pathways model which represents the structure of the 
colorectal cancer system in terms of screening, surveillance, diagnosis, treatment and 
follow-up, as well as the management of other non-malignant pathologies which impinge 
upon the colorectal cancer service (Section 1.4). 
 
1.3 A conceptual disease logic model of preclinical natural history and post-diagnosis 
risk  
Figure 1 presents a disease logic model outlining key disease-specific characteristics 
associated with colorectal cancer, both sporadic and inherited, described in terms of 
preclinical disease progression, diagnosis, clinical disease and death. This conceptual model 
should be interpreted in terms of the individual’s true underlying histology, rather than what 
is clinically known about the subject at a given point in time. The logic model includes the 
development of colorectal cancer as well as other non-malignant pathologies. Whilst 
preclinical and post-diagnosis disease events relate to continuous processes, the model 
discretises these into mutually exclusive states using endpoints commonly described within 
the clinical and epidemiological literature. For the sake of simplicity, histology is described in 
terms of the “index lesion”, that is, the most advanced adenoma or cancer present. Beyond 
lumping or splitting these states, other metrics could be used to describe disease progression, 
for example TNM tumour staging,
20
 or the separate representation of synchronous neoplasia 
(adenomas, tumours or both). Whilst a common process is used to describe preclinical disease 
progression and clinical prognosis, event risk and sojourn time in each state may differ 
markedly between particular patient subgroups. 
 
1.3.1 Disease-specific factors - Preclinical disease progression 
Disease progression prior to detection and diagnosis cannot be directly observed, however 
numerous preclinical/subclinical features of colorectal cancer have been elucidated through 
epidemiological studies and analyses of indirect evidence. These are briefly discussed below. 
 
Figure 1 Disease logic model for colorectal cancer 
Preclinical disease Clinical diagnosis and Clinical disease Death
progression intervention status
Increased risk of polyp incidence
Normal epithelium Premalignant disease Dead
(+/- non-malignant pathology)
Premalignant disease
Low-risk adenomatous polyp
(+/- non-malignant pathology)
Intermediate-risk polyp Alive, disease-free
(+/- non-malignant pathology)
High-risk adenomatous polyp
(+/- non-malignant pathology) Alive, post-relapse 
Diagnosis (operable)
Preclinical Dukes A Operable disease
(T1N0M0,T2N0M0)
Preclinical Dukes B Alive, progression-free
(T3N0M0,T4N0M0)
Preclinical Dukes C 
(AnyT,N1-3,M0) Post-progression
Preclinical Stage D Inoperable/metastatic disease
 (AnyT,anyN,M1)
Disease natural history 
 
Tumour sites 
Colorectal cancer includes carcinoma of the colon, rectum and rectosigmoid junction (ICD10 
C18-C20). 
 
Relationship between age and colorectal cancer incidence 
Approximately 32,000 newly diagnosed cases of colorectal cancer are registered in England 
and Wales each year.
21;22
 The disease is registered as the underlying cause of around 14,000 
deaths annually.
23
 The risk of developing colorectal cancer increases dramatically with 
increasing age: between the ages of 45 and 49, the crude incidence rate is around 20 per 
100,000 for men and women; above age 75, the incidence rate increases to around 400 per 
100,000 in men, and 250 per 100,000 in women.
21
 
 
Malignant transformation – the adenoma-carcinoma sequence and de novo cancers 
It is widely accepted that most colorectal cancers arise from pre-existing adenomas through 
the adenoma-carcinoma sequence.
24
 Indirect evidence suggests that a small proportion of 
cancers arise de novo, although this theory remains subject to some controversy.
25
 
 
Relationship between adenoma formation and malignancy 
Although colorectal adenomas are common by the fifth and sixth decades of life, the majority 
do not become malignant. Intermediate- and high-risk adenomas (advanced pathology i.e. 
≥1cm, villous elements, severe dysplasia, or multiple presence)5 have an increased 
predisposition to malignant transformation. Hyperplastic polyps pose a minimal risk of 
malignancy. 
 
Sporadic and inherited colorectal cancer 
Sporadic CRC accounts for between 90-95% of all cases, whilst the remainder are related to 
two inherited CRC syndromes: Familial Adenomatous Polyposis (FAP) and Hereditary Non-
Polyposis Colorectal Cancer (HNPCC). HNPCC is caused by germline mutations in tumour 
suppressor mismatch repair (MMR) genes; this may be inherited or arise as a de novo genetic 
mutation in individuals without a family history of colorectal cancer. HNPCC is associated 
with earlier onset than sporadic colorectal cancer, typically around the age of 45. FAP is 
caused by mutation in the tumour-suppressor adenomatous polyposis coli (APC) gene. FAP is 
less common than HNPCC, and is characterised by hundreds of colorectal adenomatous 
polyps, duodenal adenomatous polyps and multiple extraintestinal manifestations. Adenoma 
development begins early in life; if the bowel is not removed, cancer usually develops around 
age 20-30 years. The lifetime risk of colorectal cancer for FAP patients is close to 100%.
18
 
 
Other increased-risk groups for developing colorectal cancer 
Dysplasia is recognised as a histopathological marker for malignancy.
18
 Patients with long-
standing ulcerative colitis and Crohn’s colitis have an increased risk of developing colorectal 
cancer. Individuals with a positive family history despite the absence of genetic mutation also 
have an increased risk of developing the disease. 
 
Synchronous and metachronous neoplasia 
Neoplasia may occur as a single event. However, synchronous tumours can occur, whereby 
two primary tumours are identified at the time of diagnosis within different parts of the 
bowel, or where a primary colorectal tumour is accompanied by secondary metastases. 
Further, colorectal tumours may be accompanied by synchronous premalignant adenomas.
26
 
In a small number of cases, metachronous primary tumours may develop following the 
detection and removal of the index tumour (this is particularly common in HNPCC carriers). 
 
1.3.2 Disease-specific factors - Diagnosis 
Symptoms associated with malignant and benign colorectal pathology 
The symptomatology of colorectal cancer is similar to several non-malignant pathologies 
including haemorrhoids, diverticular disease, constipation, coeliac disease, and irritable bowel 
syndrome (IBS). Common symptoms upon presentation include rectal bleeding, change in 
bowel habit, urgency, incomplete emptying, increased frequency, mucus, abdominal pain and 
peri-anal symptoms (for example pain on defecation, weight loss, and appetite loss).
27
 Acute 
symptoms include obstipation, abdominal pain and vomiting which may indicate the presence 
of bowel obstruction. Left without intervention, obstruction may result in faecal peritonitis 
and imminent death. 
 
1.3.3 Disease-specific factors - Clinical disease 
Relationship between cancer stage and subsequent prognosis 
Cancer stage at diagnosis is a strong predictor of subsequent prognosis.
2;28
 Several staging 
classifications exist including the standard numerical staging system (I-IV), the Turnbull and 
Astler-Coller modifications
29;30
 of the Dukes’ staging system,31 and the TNM staging 
system.
20
 Table 1.1 presents the relationship between these staging systems together with 
approximate 5-year survival estimates.
28
 
 
Table 1.1 Colorectal cancer staging classifications (from Van Cutsem
28
) 
TNM  Stage Dukes’ stage (including 
Turnbull modification) 
5-year overall survival 
(likely range) 
T in situ N0 M0 0 - Likely to be normal 
T1 N0 M0 I A >90% 
T2 N0 M0 I B 
 
85% 
T3 N0 M0 IIa 70-80% 
T4 N0 M0 IIb 
T1-2 N1 M0 / T2 N2 M0 III C 25-60% 
T3 N1 M0 / T3 N2 M0 III 
T4 N1 M0 III 
Any T any N M1 IV D 5-30% 
 
Colorectal cancer recurrence 
Following resection of the primary tumour, some patients will develop recurrence (relapse). 
Recurrence may be anastomotic (at the area of anastomosis), locoregional (at the site in the 
abdomen of previous disease, and/or in the lymph nodes, but not necessarily in the bowel) or 
distant (spread to other organs, most commonly the liver and the lungs). Local relapse is a 
common problem for rectal cancer. Whilst local relapse rates tend to be low for colon cancer, 
this may be due to under-reporting (Personal communication: Dr Rob Glynne-Jones, 
Consultant Oncologist, Mount Vernon Cancer Centre). Broadly speaking, the risk of distant 
relapse increases with Dukes’ stage. With the exception of a small proportion of patients in 
whom further resection is possible, the prognosis for patients with metastatic disease is poor, 
hence a key goal of adjuvant treatment is the avoidance of relapse. The risk of relapse is 
believed to be very low five years after surgical resection of the primary tumour.
32
 
 
Potentially curative treatment for distant metastases 
Resection of liver metastases may enable long-term cure in a small number of patients with 
distant metastases, although this depends on the number, location and extent of metastases 
and the volume of remaining liver following resection. In a lesser number of patients, similar 
benefits may be seen following the resection of pulmonary metastases. 
 
1.3.4 Disease-specific factors - Death 
Generally speaking, death due to colorectal cancer is a result of two specific causes: death due 
to metastatic disease and tumour burden, and in a lesser number of cases, faecal peritonitis 
resulting from bowel obstruction. 
 
1.4 Conceptual service pathways models for colorectal cancer (Stage 2a) 
A basic service breadth model describing the main components of the colorectal cancer 
service was previously outlined in Figure 3.1 and is therefore not reproduced here. This 
section draws out the complexity of the main colorectal cancer service pathways in England 
and Wales by presenting a series of diagrammatic service depth models together with 
supporting textual description. Owing to the size and complexity of the cancer system, the 
service pathways model is divided into nine related modular components: 
Pathway A – Colorectal cancer presentation, referral and diagnosis 
Pathway B – Treatment of colon cancer 
Pathway C – Treatment of rectal cancer 
Pathway D – Colorectal cancer follow-up after surgery with curative intent 
Pathway E – Treatment of metastatic colorectal cancer 
Pathway F – Surveillance of individuals with adenomatous polyps 
Pathway G – Surveillance, diagnosis and treatment of FAP 
Pathway H – Surveillance and management of HNPCC  
Pathway I – Surveillance of long-standing ulcerative colitis/Crohn’s disease 
1.4.1 Pathway A – Colorectal cancer presentation, referral and diagnosis 
Patients with significant colon or rectal pathology may present in a variety of ways. The most 
common entry routes for a diagnosis of colorectal cancer and other colorectal pathologies are: 
1. Early detection via colorectal cancer screening. 
2. Symptomatic clinical presentation to a GP; 
3. Presentation at an A&E department; 
4. Referral from elsewhere in secondary care; 
 
The four main colorectal cancer diagnostic pathways (GP, A&E, secondary care referral and 
screening) are discussed in this section. A diagrammatic representation of current diagnostic 
pathways is presented in Figure 1.2. 
 
As noted above, certain groups of patients are known to have an increased risk of developing 
colorectal cancer, these include: 
 Individuals who are identified with FAP; 
 Individuals who are identified with HNPCC; 
 Individuals who are identified as having adenomatous polyps; 
 Individuals with long-standing Crohn’s disease or ulcerative colitis (UC); 
 Individuals with a positive family history with or without a known genetic mutation. 
 
Whilst many individuals with FAP and HNPCC will have been identified through linkage 
(family history) analysis or through a clinical genetics department, some will present 
symptomatically through the main diagnostic pathways described in Figure 1.2. In particular, 
some cases of FAP and HNPCC will arise due to a de novo genetic mutation, hence they will 
not have a family history, but will instead be picked up as they develop symptoms. 
Asymptomatic individuals with a positive family history may also be invited to attend COL 
screening between the ages of 35 and 55. Patients may also enter the system through the 
surveillance of non-malignant conditions such as ulcerative colitis, Crohn’s disease or 
through surveillance of individuals with a history of adenomas; these entry routes are detailed 
in Pathways I and F. 
 
Diagnosis route 1 – Participation in colorectal cancer screening 
Colorectal cancer screening using biennial guaiac FOBT has recently been rolled out across 
England for individuals aged 60-69 years. A programme extension up to age 74 is currently in 
implementation. Individuals are sent an FOBT kit and are asked to collect 2 samples from 
each of 3 separate bowel motions.
33
 Participants are required to return completed FOBT kits 
for analysis within 14 days of collecting the first sample. In the event that the test result is 
unclear, spoilt or subject to a technical failure, 1-2 repeat tests may be dispatched.  
Figure 1.2 Main diagnostic pathways for colorectal cancer 
Patient discharged
Patient does not attend
Patient does not attend
Patient doesn't participate Completely normal 
Test abnormal Patient referred for follow-up COL Clinic visit with screening nurse practitioner findings
Counselled to have COL
Patient receives Patient history & examination
FOBT test
Test normal
Patient not invited for COL Positive findings through surveillance of increased-risk groups
Unclear result/spoilt kit (1-2 repeat test) Patient consents
to follow-up MDT referral from elsewhere in secondary care
Re-invited to screening investigation
patient sent home
Family history screening
CT chest, abdomen & pelvis COLON CANCER 
colonic tumour or abdominal US and CXR TREATMENT PATHWAY (i)
sent home histologically confirmed Baseline CEA test
FBC & EUC HNPCC/FAP PATHWAY
Not referred Discussed at MDT
Symptoms missed/
not suspicious fit for endoscopy
Attend colorectal OP clinic (consultant-/nurse-led) rectal/rectosigmoid tumour CT chest, abdomen & pelvis +/-MRI RECTAL CANCER 
Referral criteria Patient history & examination Attend endoscopy suite histologically confirmed Baseline CEA test TREATMENT PATHWAY (i)
Clinical presentation to GP met 2-week wait PR examination FSIG FBC & EUC
Rigid sigmoidoscopy (not if straight to investigation) or  COL Discussed at MDT
Criteria not met Haemaglobin check or FSIG→COL adenomatous 
Proctoscopy (if presence of rectal bleeding) polyps found
Not 2-week wait
emergency ADENOMA
symptoms significant findings( ↑) Polypectomy via snare diathermy SURVEILLANCE 
incomplete COL(↓) other non- /EMR/surgical excision PATHWAY
Emergency unfit for COL/ malignant 
referral lack of resources/ pathology
symptoms Tests for other diagnoses(e.g. coeliac Surveillance/treatment of non-
not obstructed disease, haemorrhoids, FAP/HNPCC) malignant pathologies
internal 2-week carriers
wait or not no tumour 
found
Attend radiology suite
Abdominal US (if palpable mass)+ CT abdomen&pelvis (CT chest later)
or CT pneumacolon (if frail and available)
Attend A&E See triage nurse and A&E doctor or BE (most likely if COL incomplete)
Patient not using Patient history & examination straight to theatre based on clinical findings & X-rays
bowel cancer Maybe PR examination
service Emergency Haemaglobin check
presentation Plain abdominal Xray Unfit/patient No treatment Best supportive care
suspected obstructed choice Discussed at MDT
Not urgent/missed or PR bleeding 
Present to emergency healthcare or abdominal pain CEA test
professional (GP/nurse/paramedic) Referred elsewhere CT abdomen pelvis +/-chest Fit
/sent home +/-water soluble contrast enema Surgical intent COLON CANCER 
probable Maybe FSIG Discussed at MDT TREATMENT PATHWAY (ii)
colon cancer Successful stent as 
bridge to surgery
Fit
Emergency Stenting
treatment CT chest abdomen pelvis (if 
not already done)
Discussed at MDT Unsuccessful/ Best supportive care
palliative/complication
Unfit/patient No treatment Best supportive care
probable choice Discussed at MDT
rectal cancer
CEA test
CT abdomen pelvis Fit
+/-water soluble contrast enema Surgical intent RECTAL CANCER 
Maybe FSIG Discussed at MDT TREATMENT PATHWAY (ii)
Successful stent as 
bridge to surgery
Fit
Stenting
CT chest abdomen pelvis
Discussed at MDT
Unsuccessful/ Best supportive care
palliative/complication
straight to theatre based on clinical findings & X-rays
straight to theatre based on clinical findings & X-rays
Referral from elsewhere
in secondary care
(CT/COL/US done elsewhere) Straight to MDT discussion if diagnostic investigations already done
Surveillance of Crohn's, UC, adenomas
Genetic testing/ Management of HNPCC pathway
linkage analysis
for HNPCC/FAP Management of FAP pathway
Individuals who fail to return the completed test kit are sent a reminder letter. Subjects in 
whom a normal test result is obtained are re-invited to participate in the next screening round 
provided they still meet age eligibility criteria and provided they have not opted out of the 
programme. Subjects in whom an abnormal test result is found are invited to attend a clinic 
visit with a screening nurse practitioner to discuss whether they wish to undergo a follow-up 
COL, to answer any questions about the procedure and to assess the patient’s fitness to 
undergo COL.
33
 The subject may decline this invitation; these individuals would likely be re-
invited to participate in the next screening round provided they are still eligible. If they test 
positive at the subsequent screening round and again decline the invitation to the nurse clinic, 
the patient’s GP would be informed and they would no longer be invited to participate in the 
programme (Personal communication: Julietta Patnick, Director, NHS Cancer Screening 
Programmes, Sheffield). For subjects who attend the clinic, COL would be the investigation 
of choice, however complete COL to the caecum may not be possible in some patients. In 
such instances an alternative test, for example barium enema (BE) or CT colonography (CTC) 
may be used. Subsequent diagnostic pathways are identical to those for symptomatic patients. 
 
Diagnosis route 2 – Patients who present symptomatically to their GP 
Patients who present symptomatically to their GP and are either referred or not (appropriately 
or missed), based upon current guidelines for the referral of patients with suspected colorectal 
cancer.
3
 The GP may undertake certain investigations themselves which trigger the decision 
to refer, for example screening blood tests, liver function tests and US examinations. Where 
referral is deemed appropriate, there are three broad options: 
(1) Fast-track referral (“2-week wait”)  - where one or more of the following symptoms and 
signs occur: 
 Rectal bleeding with a change in bowel habit towards looser stools and/or increased 
frequency of defecation persistent for 6 weeks (≥40 years of age). 
 Rectal bleeding persisting for 6 weeks or more without a change in bowel habit and 
without anal symptoms (≥60 years of age). 
 Change in bowel habit towards looser stools and/or more frequent stools persisting 
for 6 weeks or more without rectal bleeding (≥60 years of age). 
 Right lower abdominal mass consistent with involvement of the large bowel (all 
ages). 
 Palpable rectal mass (intraluminal and not pelvic, all ages). 
 Unexplained iron deficiency anaemia and a haemoglobin of 11g/100ml or below 
(men, all ages). 
 Unexplained iron deficiency anaemia and a haemoglobin of 10g/100ml or below 
(non-menstruating women).
3
 
(2) Emergency admission - if the patient has acute obstructive symptoms such as obstipation, 
abdominal pain (although this may be present without obstruction) and vomiting, or non-
obstructive symptoms such as profound rectal bleeding, they may be referred directly to 
A&E. 
(3) Standard referral - not “2-week wait” i.e. where the above criteria are not met. 
 
Patients who are referred either as a “2 week wait” or as a standard referral are invited to 
attend a normal clinic which may be either nurse- or consultant-led. At the clinic: 
 All patients would undergo a general consultation (patient history and general 
examination e.g. abdominal examination); 
 All patients would have a per-rectal (PR) examination to determine whether the 
patient has a palpable mass in their rectum or anal canal; 
 All patients would undergo either a rigid sigmoidoscopy or FSIG to look for the 
presence of rectal cancer. FSIG is currently less common at this stage although may 
sometimes be used as “straight to investigation” on the basis of symptoms described 
in the referral letter from the GP, perhaps via a specialist nurse-led one-stop clinic; 
 Most patients would have a haemoglobin check undertaken by a phlebotomist; 
 If there is evidence of rectal bleeding, the patient would also have a proctoscopy 
which allows for the visualisation of the anal canal (usually looking for 
haemorrhoids, visualising around 8 cm of the anal canal and rectum). 
 
From the clinic, the patient would either attend an endoscopy suite or a radiology suite. 
 
If the patient attends the endoscopy suite, investigative options include: 
 FSIG - if this suggests the presence of cancer or adenomas, the patient would undergo 
COL to rule out synchronous disease; 
 COL - this is the gold standard diagnostic investigation, however this carries the greatest 
risk of perforation and subsequent complications. If complete COL to the caecum is not 
possible, the patient may undergo a completion BE in the radiology suite. The use of 
diagnostic CTC is increasing and is likely to lead to the phasing out of BE, however this 
is not available in all centres. 
 
If the patient attends the radiology suite following the clinic visit, they will undergo one of 
three investigations: 
 If a palpable mass is found during the abdominal examination in the clinic, the patient 
may have a CT scan of their abdomen and pelvis (they would receive a chest CT later); 
 A BE which is performed by a radiographer/supervising radiologist and reported by a 
radiologist or a radiographer. BE may be elected in place of endoscopy based on the 
patient’s symptoms, particularly abdominal pain and constipation, or where a diagnosis of 
diverticular disease is considered more likely than cancer. Alternatively BE, may be 
elected for patients who are unfit for COL. 
 If the patient is frail, they may undergo CTC performed by a radiographer/supervising 
radiologist and reported by radiologist (subject to availability of this technology). 
 
Each of the above investigations carries a small risk of complications such as colonic 
perforation either due to bowel preparation or the procedure itself. The majority of 
perforations manifest symptomatically shortly after the test. Many perforations can be 
managed conservatively, however some will require emergency surgery. Conservative 
management may be followed by repeated radiological investigation, most likely BE. 
 
Patients with a completely normal diagnosis on the basis of the above tests may be discharged 
at this point. If a tumour is found at endoscopy, the patient will undergo staging of the chest, 
abdomen and pelvis via a CT scan or abdominal US and chest x-ray (CXR). If a tumour is 
found at radiology, the patient will attend the endoscopy suite for direct bowel 
visualisation/biopsy via COL to rule out synchronous disease. If the patient has not already 
undergone a CT scan of their chest, they will do so at this point. Right-sided or transverse 
colon tumours are not necessarily visualised and biopsied, although two criteria of 
malignancy should be fulfilled before resection such as a positive BE and anaemia, a positive 
CT scan, or presence of a palpable mass. Diagnosis can only be confirmed through 
histological confirmation via biopsy; where this is not possible, e.g. emergencies or patients 
who do not undergo endoscopy, diagnosis is confirmed later via resection histology. 
 
If the neoplasia is rectal or rectosigmoid, most patients receive an MRI and CT scan, with the 
remainder undergoing CT alone. Patients with a positive diagnosis of colorectal cancer may 
have a baseline CEA test and appropriate treatment options or palliation would be discussed 
at a Multidisciplinary Team (MDT) meeting. A full blood count (FBC) and electrolytes, urea 
and creatinine (EUC) examination are also undertaken. 
 
If the patient is diagnosed with other non-malignant pathology but is considered to be at an 
increased-risk of subsequently developing colorectal cancer due to the presence of adenomas, 
they will have their polyps removed through polypectomy with snare diathermy or 
endoscopic mucosal resection (EMR). This may require a second visit if the endoscopist is 
not proficient in EMR. These patients are subsequently offered endoscopic surveillance using 
COL, in line with BSG guidelines
5
 (see Pathway F). In a small number of cases it will not be 
possible to remove adenomas via polypectomy and surgery may be required. Other non-
neoplastic diagnoses such as hyperplastic minimal risk polyps are either left in situ or 
removed by polypectomy with snare diathermy, usually without subsequent surveillance. 
Individuals with other non-malignant pathologies may be offered further tests to establish a 
diagnosis and possibly further treatment; these patients would be subsequently be managed by 
a medical team. 
 
Diagnosis Route 3 – Presentation at A&E 
Patients may present either at an A&E department directly, or may be referred to A&E as an 
emergency admission after seeing their GP, or following a visit from an emergency care 
practitioner (nurses or paramedics). The patient would see a triage nurse to establish how 
quickly they need to be seen. The patient would then see an A&E doctor who would take their 
history, undertake a general examination (with or without a PR examination) and arrange 
simple investigations as deemed appropriate i.e. blood tests and plain abdominal x-ray, based 
on a number of factors, such as abdominal pain, or concerns regarding obstruction. Patients 
believed to be suffering from obstruction would be referred directly to surgery on the basis of 
their history and general examination only (the need for admission depends on symptoms at 
presentation). Only rarely do patients present at A&E with haemorrhage sufficient to warrant 
emergency admission; whilst many patients present with PR bleeding, most will settle 
spontaneously and can be subsequently investigated in an outpatient setting. A proportion of 
individuals presenting at A&E would be referred elsewhere if their diagnosis is considered to 
be non-surgical. For example, patients presenting with symptoms of gastroenteritis such as 
abdominal pain and diarrhoea may be referred to a medical team, mainly based on their 
history, however an abdominal x-ray may be ordered to rule out obstruction, and blood tests 
will be done as part of their work-up. A more common route of referral is with iron deficiency 
anaemia, presenting to the physicians/A&E with cardiac failure, angina, myocardial 
infarction, or shortness of breath. Patients without urgent symptoms may be sent home or 
referred for diagnostic investigations either as an internal 2-week wait or standard referral. A 
proportion of individuals presenting at A&E directly will be sent home if diagnostic 
investigations do not suggest the presence of significant colorectal pathology, benign or 
otherwise. 
 
If the patient is thought to be obstructed due to the presence of a colorectal tumour, they may 
receive a CEA test, however this is sometimes not done at baseline due to the emergency 
context of care. The patient may also receive a CT of their abdomen and pelvis prior to 
surgery (again this may not happen due to the emergency context). For these patients, CT is 
used to look for the cause of the patient’s symptoms such as obstruction secondary to the 
tumour. As these patients would not have undergone COL, a biopsy specimen would not be 
available for histological confirmation. A radiologist would report on any evidence of 
metastases and thus stage the patient. A water soluble contrast enema may also be used to 
assess whether the patient is suffering from complete obstruction or pseudo-obstruction. 
 
In some cases, the patient will go straight to theatre without undergoing further imaging based 
on their clinical findings (i.e. the patient’s history and examination) and erect chest and 
abdominal film x-rays. These patients would not undergo a CT of their abdomen and pelvis, 
contrast enema or MRI if the cancer is rectal. Imaging would instead be undertaken 
postoperatively if the patient recovers from their emergency surgery. It is also possible that a 
patient may not undergo any imaging whatsoever; for example if a patient is admitted unwell 
with peritonitis (secondary to a perforated tumour) they may go straight to theatre, with all 
imaging taking place postoperatively. 
 
If complete obstruction is confirmed, the patient may: 
1. Receive no active intervention if they are severely compromised by co-morbidity. These 
patients would subsequently receive supportive care, but may perforate and die of faecal 
peritonitis imminently or succumb to the effects of obstruction. 
2. Go straight to surgery without CT. Once recovered, these patients would subsequently 
have a chest CT (plus a CT of their abdomen and pelvis if not previously done). The 
patient would then be discussed at an MDT meeting to determine further appropriate 
treatment and confirm histological diagnosis. 
3. Undergo stenting. Stenting would be done by a consultant radiologist or consultant 
endoscopist with a subsequent CT scan of their chest (the patient would also undergo a 
CT scan of their abdomen and pelvis if not previously done). The patient would then be 
discussed at an MDT meeting to determine subsequent treatment. Stenting may be done 
for two reasons: either (a) to act as a bridge to elective surgery i.e. to make the patient 
nutritionally and medically fit for surgery with a view to reducing mortality, or (b) to 
relieve obstruction in a patient who is either unfit or has extensive metastatic disease so 
that they do not suffer subsequent perforation or undergo unnecessary emergency surgery 
when cure is impossible. In both instances, stenting allows the clinician to “buy time” to 
make a more informed decision about what is in the patient’s best interests. If the 
intention is to buy time to optimise the patient for surgery, and the stenting is successful, 
the patient may later undergo surgery. If the stenting is unsuccessful or if the patient has a 
stent complication of perforation, the patient will go on to have emergency surgery at that 
point if they are deemed sufficiently fit. If the intention is to use stenting to relieve 
obstruction in an unfit patient or one with widespread incurable metastatic disease, and 
stenting is successful, the patient will subsequently receive palliative/supportive care. If 
the stenting is unsuccessful and the patient is unfit for further treatment, they will die of 
faecal peritonitis imminently. These patients would not receive further imaging. 
 
Diagnosis Route 4 – Referral from elsewhere in secondary care 
Some patients enter the colorectal cancer system from elsewhere in secondary care, having 
previously undergone diagnostic investigations undertaken by another medical team (usually 
either CT or COL which suggest probable cancer), hence these patients are referred directly to 
the MDT. If the patient has symptoms but has not undergone diagnostic investigations, they 
may go to clinic first (see Diagnostic Route 2). 
 
1.4.2 Pathway B – Treatment of colon cancer 
Figure 1.3 presents the main pathways for the treatment of patients who have a positive 
diagnosis of colon cancer. 
 
Treatment of patients who are operable with preoperative curative intent 
If the patient is operable, if there is no evidence of advanced disseminated disease, and if they 
consent, they would undergo surgical resection of the primary tumour (with or without prior 
stenting to optimise the patient - see Pathway A). Some patients who undergo stenting as a 
bridge to surgery may not subsequently undergo surgery. Some surgeons may require the 
patient to undergo mechanical bowel preparation i.e. enemas or purgatives such as Picolax, 
given the day before their surgery. In addition, patients may receive thromboembolism 
prophylaxis to avoid deep vein thrombosis (DVT) and pulmonary embolism, either using low-
molecular weight heparin, graduated compression stockings, and intermittent pneumatic calf 
compression. All patients should receive antibiotic prophylaxis, usually at the induction of 
anaesthesia, to avoid postoperative sepsis. The patient would also undergo bladder 
catheterisation to monitor urine output during and after the operation, usually following 
anaesthetisation. Surgical excision is most likely to be a right-, extended right-, subtotal-, left-
hemicolectomy, or high anterior resection (AR). Excision may be open or laparascopic.
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 If 
the tumour is not deemed fit for anastomosis (suturing or stapling of remaining colonic 
mucosa) due to technical impossibility or unacceptable patient risk, other techniques such as 
Hartmann’s procedure may be used. 
 
Some metastases may be missed by the diagnostic pathway (Pathway A) and later found at 
surgery; even in such instances, the primary tumour would still be resected unless 
unresectable locally advanced disease is identified during surgery. 
Figure 1.3 Treatment pathways for colon cancer 
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Following surgery, patients typically remain in hospital for around 3-10 days. Longer may be 
required if the patient needs to learn how to manage their stoma, if they experience 
complications, or if their recovery is slow (Personal Communication: Dr Janine Yusuf, 
Surgical Registrar, Northern General Hospital, Sheffield). During recovery in hospital, 
nursing support is required to monitor blood pressure and pulse, drug administration and to 
provide general care. Physiotherapy support may also be required for mobilisation. 
 
For elective cases, radiological staging and histological assessment of biopsy specimens 
would take place prior to surgery, and would be confirmed histologically post-surgery. For 
patients presenting as emergency cases, histological confirmation would be undertaken via 
examination of the resection specimen. Histology would typically be discussed with the 
patient around 6-weeks following surgery. 
 
Following surgical resection and recovery, patients with Dukes’ C colon cancer who are 
sufficiently fit will be offered adjuvant chemotherapy. Treatment usually commences 6 to 8 
weeks following surgery if possible. NICE currently recommends 5-FU/FA, oxaliplatin plus 
5-FU/FA and capecitabine as adjuvant chemotherapy options for Dukes’ C colon cancer. In 
practice, oxaliplatin is sometimes used in combination with capecitabine. Adjuvant 
chemotherapy is given for a period of up to 6-months, although patients may discontinue 
treatment due to recurrence or unacceptable treatment-related toxicities.
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 Patients with 
Dukes’ B colon cancer who are deemed to be at high-risk of relapse may also be offered 
adjuvant chemotherapy using 5-FU/FA based regimens, although the relationship between 
risk status and the clinical benefits of chemotherapy is unclear.
2
 The decision to offer Dukes’ 
B patients chemotherapy is likely to be influenced by the degree of extramural vascular 
invasion, poorly differentiated tumours (abnormal appearance of cells under a microscope), 
serosal involvement, the presence of perforation or obstruction, younger age, and patient 
choice. In some centres just one of these features may be enough to trigger the decision to 
offer adjuvant chemotherapy (Personal communication: Professor Matt Seymour, Professor 
of Gastrointestinal Medicine, University of Leeds). Following surgical resection, patients 
would be followed up according to local protocols (see Pathway D). 
 
Management of patients with operable or potentially operable metastatic disease 
A proportion of patients present with distant metastases, some of which will be immediately 
resectable at presentation; this is most likely to be where the patient has metastases which are 
confined to the liver, or in a smaller proportion of cases, the lungs. If resectable, the primary 
tumour will usually be resected some weeks before the metastases (staged resection). In some 
cases, chemotherapy may render metastases resectable. NICE does not have a separate 
recommendation concerning the use of irinotecan or oxaliplatin in this indication, although 
current guidance implies that either irinotecan or oxaliplatin could be used.
12
 More recently, 
NICE has recommended the use of cetuximab plus 5-FU/FA and oxaliplatin (FOLFOX) or 
irinotecan (FOLFIRI) as a downstaging treatment for patients with metastatic colorectal 
cancer when all of the following clinical criteria are met: 
 The primary colorectal tumour has been resected or is potentially operable; 
 The metastatic disease is confined to the liver and is unresectable;  
 The patient is fit enough to undergo surgery to resect the primary colorectal tumour 
and to undergo liver surgery if the metastases become resectable after treatment with 
cetuximab.
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The success of downstaging chemotherapy of liver metastases would be assessed using CT or 
MRI after a small number of treatment cycles. If downstaging is successful, the patient may 
undergo surgical resection. Patients who undergo hepatic resection would subsequently be 
followed up by liver surgeons, whilst those undergoing pulmonary resection would be 
followed-up by cardiothoracic surgeons. If downstaging is unsuccessful, patients would 
receive palliative interventions; this may involve continuing the same regimen of 
chemotherapy. 
 
Treatment of patients who are inoperable 
Patients with inoperable colon cancer may undergo palliative stenting, or receive a 
defunctioning stoma, a palliative bypass (without resection of the tumour), palliative 
chemotherapy, or supportive/palliative care (see Pathway E). 
 
1.4.3 Pathway C – Treatment of rectal cancer 
Figure 1.4 presents the main treatment pathways for patients who have a positive diagnosis of 
rectal cancer. The adjuvant treatment of rectal cancer differs from that for colon cancer, 
principally due to the benefits of chemoradiation (radiation plus concurrent chemotherapy) or 
radiation alone. Adjuvant chemotherapy may be used within similar indications to those for 
colon cancer (see Pathway B). Radiation therapy and/or chemotherapy may be used either 
pre-operatively or post-operatively in the adjuvant treatment of rectal cancer. 
 
Management of patients who are operable with pre-operative curative intent 
Unless presenting as an emergency, most rectal cancer patients undergo an MRI scan plus a 
CT scan, with the remainder undergoing a CT scan alone (see Pathway A). The results of the 
MRI scan are central in determining subsequent appropriate elective treatment. 
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MRI predicts R0 resection (all margins histologically free of tumour) 
Two main surgical procedures are used in the excision of rectal tumours: abdominoperineal 
resection (APER) and anterior resection (AR), although other techniques have been used.
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Both APER and AR can be undertaken alongside total mesorectal excision (TME). The 
choice of resection technique is guided primarily by tumour location within the rectum. If the 
tumour is in the lower third of the rectum and the rectal MRI scan suggests that an R0 
resection is possible, the surgeon will likely plan to undertake an APER. Conversely, if the 
tumour is in the upper two thirds of the rectum, it is likely that the surgeon will plan to 
undertake an AR. Some lower third rectal cancers are amenable to low AR, provided that 1cm 
distal clearance can be obtained and the MRI predicts an R0 resection. Decisions concerning 
the use of AR/APER will also depend on likely bowel function following surgery and patient 
preference. 
 
Prior to surgical excision, some patients may undergo short-course pre-operative radiotherapy 
to reduce the risk of LR even if the tumour is fully mobile and easily resectable. Short-course 
pre-operative radiotherapy is given as five fractions of 25Gy over 5 days. A proportion of 
patients will undergo surgery without pre-operative radiotherapy. Resection histology would 
be confirmed following surgery and discussed at an MDT meeting. If CRM involvement is 
confirmed after surgery, patients who have not previously received radiotherapy may be 
offered post-operative chemoradiation, typically involving 5 weeks of radiation therapy plus 
concurrent chemotherapy using a 5-FU/FA based regimen or capecitabine. Patients in whom a 
successful R0 resection is achieved would not undergo further resection or post-operative 
chemoradiation. Patients may subsequently be offered adjuvant chemotherapy using 5-FU/FA 
based regimens according to local protocols, fitness and perceived risk of relapse. The 
decision to offer adjuvant chemotherapy is typically based on lymph node involvement, CRM 
involvement, extramural vascular invasion, pT4, acute presentation with obstruction, and 
tumour perforation. 
 
MRI predicts R1/R2 resection (margins involved) 
If the MRI predicts an R1/R2 resection, the patient would be offered long-course pre-
operative radiotherapy (with or without 5-FU/FA based chemotherapy, dependent on whether 
the patient is able to tolerate treatment-related toxicities) to downsize the tumour. Long-
course pre-operative radiotherapy (with or without concurrent chemotherapy), typically given 
as 25-28 fractions at 45Gy-50.4Gy, is used for macroscopic tumour shrinkage to facilitate 
successful resection, to reduce LR risk, and to increase the probability of sphincter 
preservation. Long-course chemoradiation is often used for MRI-predicted CRM involvement 
or for bulky, node-positive predicted T3 tumours. A pre-treatment loop ileostomy would 
usually be fashioned. Patients who receive long-course radiation therapy undergo a 
laparoscopic or trephine defunctioning stoma to stop the bowel motion passing the irradiated 
field thereby avoiding complications and patient discomfort. The success of downsizing pre-
operative therapy would be assessed by MRI. If the MRI results are equivocal for operability, 
the patient may have an examination under anaesthetic (EUA). Assessment for operability 
takes place around two months after completion of 5 weeks of chemoradiation. If the tumour 
remains inoperable, a further period of two months is advisable before reassessing for 
operability with or without EUA. Results would be discussed within an MDT setting. Surgical 
preparation (bowel preparation unless defunctioned by loop ileostomy prior to long-course 
chemoradiation, thromboembolism prophylaxis, and antibiotic prophylaxis) is required (see 
Pathway B). If the tumour is successfully downsized, the patient would undergo surgery (note 
that downsizing after chemoradiation may permit a restorative AR). The patient may be 
offered adjuvant chemotherapy using 5-FU/FA based regimens. If downsizing is 
unsuccessful, the patient would receive palliative/supportive care. 
 
As with colon cancer, if the patient presents with synchronous metastases, it may be possible 
to resect part of the liver and/or the lungs (see Pathway B). If resectable, the primary tumour 
will be resected some weeks before the metastases. If the metastases are not initially 
resectable, it may be possible to downstage a proportion of tumours using chemotherapy. The 
success of downstaging would be assessed using CT or MRI. If downstaging is successful, 
patients would undergo surgical resection and would subsequently be followed up by 
surgeons. If downstaging is unsuccessful, remaining treatment options would be palliative 
(see Pathway E). 
 
Management of patients who are inoperable 
Patients who present as an emergency may undergo a Hartmann’s procedure or receive a 
defunctioning stoma to relieve the obstruction. This may render the tumour operable, in which 
case the patient would be staged and subsequently follow the pathways for operable rectal 
cancer described above. If perforated, a subtotal colectomy with ileostomy is likely to be 
required. Palliative stenting is unlikely to be a viable option for the majority of rectal cancer 
patients due to the technical impossibility of stent insertion low in the rectum, the patient’s 
awareness of the stent, and the likelihood of patient intolerance due to tenesmus (an 
ineffectual urge to evacuate the bowels). The remainder would be treated palliatively. 
Palliative treatment of rectal cancer is typically similar to that for colon cancer in terms of the 
chemotherapy options available (see Pathway E). If the patient has not previously received 
radiotherapy, they may also be offered dose-limited palliative radiotherapy for metastatic 
disease. 
1.4.4 Pathway D Colorectal cancer follow-up after surgery with curative intent 
As noted in Chapter 5, a “gold standard” follow-up regimen does not exist; the timing and 
frequency at which each investigation is undertaken varies markedly between centres.
34
 
Figure 6.8 in the previous chapter presented the follow-up schedule recommended by the 
North Trent Cancer Network;
35
 however this is not reflective of many cancer centres with 
respect to the types, quantities or timing of investigations used. Figure 1.5 presents the results 
of a recent ad hoc survey of the Royal College of Radiologists. This survey highlights 
considerable variation in the use of CEA, CT and US as part of routine colorectal cancer 
follow-up (provided through personal communication with Dr Rob Glynne-Jones, Consultant 
Oncologist, Mount Vernon Cancer Centre). 
 
Figure 1.5a Variation in CT/US tests offered each year by centre within sample 
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Figure 1.5b Variation in CEA tests offered each year by centre within sample 
0%
20%
40%
60%
80%
100%
Year 1 Year 2 Year 3 Year 4 Year 5
P
e
rc
e
n
ta
g
e
 o
f 
c
e
n
tr
e
s
0 1 2 3 4 5 6
Number of CEA tests in year
 
Irrespective of the follow-up schedule adopted, relapse in patients undergoing routine follow-
up may be identified through abnormal rises in CEA, abnormal results identified through 
radiological imaging or COL, or symptomatic presentation during the interval between 
scheduled follow-up visits. These patients may re-present via their GP or as emergency cases 
(see Pathway A), or alternatively they may present with symptoms at scheduled follow-up 
appointments. If CT or MRI of the liver/pelvis suggests recurrence, the patient may be offered 
further surgical resection, or downstaging/palliative chemotherapy as described in Pathways 
B, C and E. 
 
1.4.5 Pathway E Treatment of metastatic colorectal cancer 
For those patients who will not benefit from further surgery, treatment options are essentially 
palliative, and are intended to control symptoms and improve HRQoL. Survival benefits in 
this patient group are only possible through the use of active chemotherapy, although these 
are typically modest, even for newer agents.
7;8;36
 If sufficiently fit, and they choose to receive 
further active treatment, patients may be offered chemotherapy using a variety of alternative 
regimens (see Figure 1.6). 
 
Figure 1.6 Chemotherapy pathways for unresectable metastatic colorectal cancer 
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NICE currently recommends infusional 5-FU/FA, alone or in combination with irinotecan or 
oxaliplatin as first-line and second-line treatment options for the management of advanced 
CRC.
12
 Most commonly, 5-FU/FA-based regimens for advanced CRC are given according to 
the modified de Gramont regimen in the UK. This involves an initial bolus and subsequent 
infusional components which allow the majority of chemotherapy to be administered in an 
outpatient setting over 2-weekly cycles.
37
 There is some evidence that giving all three 
cytotoxic drugs is better than two,
38
 hence the optimal recommended treatment sequences are 
likely to be either 5-FU/FA plus irinotecan followed on progression by 5-FU/FA plus 
oxaliplatin or the reverse sequence, although treatment options are guided by patient 
preferences, tolerability of adverse events and patient fitness. Some patients will receive only 
a single line of therapy. Other treatment options include capecitabine and tegafur with uracil 
(UFT).
13
 Following disease progression on second-line chemotherapy, a small proportion of 
patients may subsequently receive third-line salvage chemotherapy; this is likely to be 
mitomycin-C plus protracted 5-FU (Personal Communication: Dr David Radstone, 
Oncologist Clinical Oncologist, Royal Devon and Exeter NHS Foundation Trust), although 
there is currently no firm guidance on which therapy should be used. Cetuximab is not 
currently recommended by NICE,
15
 except in the downstaging of liver metastases which may 
subsequently become amenable to subsequent resection (maximum of 16 weeks treatment). 
Raltitrexed is not recommended in any indication,
12
 but is used in some centres for a minority 
of patients who develop coronary artery spasm and therefore cannot receive 5-FU/FA based 
regimens. Bevacizumab is currently under appraisal by NICE as a first-line treatment. 
 
1.4.6 Pathway F Surveillance of individuals with adenomatous polyps 
Figure 1.7 presents the BSG guidelines for the surveillance of individuals in whom colorectal 
adenomatous polyps are found; this algorithm is described below.
5
 Whilst patients are 
undergoing surveillance it is unlikely that they would be invited to attend screening. 
Adenoma surveillance is not usually recommended beyond the age of 75 years. 
 
Management of low-risk individuals (1-2 small [<1cm] adenomas) 
Individuals in whom low-risk adenomas are identified would undergo polypectomy and 
subsequently receive either no follow-up or COL after 5-years. If the follow-up COL 
indicates no further polyps, the patient would be discharged. If surveillance COL at 5-years 
indicates intermediate- or high-risk adenomas, they would follow surveillance pathways 
below. 
 
Management of intermediate-risk individuals (3-4 small adenomas, or at least one >1cm) 
Individuals in whom intermediate-risk adenomas are detected would undergo polypectomy 
and 3-yearly surveillance COL. If the individual receives 2 consecutive negative COL 
examinations, they would be discharged. If low- or intermediate-risk adenomas are detected 
at follow-up, they would return to the beginning of this pathway. If high-risk adenomas are 
detected at follow-up, they would enter the high-risk pathway. 
 
Management of high-risk individuals (≥5 adenomas or ≥3 adenomas with at least one >1cm) 
Individuals in whom high-risk adenomas are detected would undergo polypectomy and a first 
surveillance COL after 1 year. If this COL identifies no adenomas, low- or intermediate-risk 
adenomas, the individual would enter the intermediate-risk pathway. If further high-risk 
adenomas are identified, the individual would then re-enter the high-risk surveillance 
pathway. 
Figure 1.7 Surveillance pathways for colorectal adenomatous polyps (following baseline COL and polypectomy) 
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1.4.7 Pathway G Surveillance, diagnosis and treatment of Familial Adenomatous Polyposis 
Typical pathways for the surveillance and management of FAP are presented in Figure 1.8. 
 
Figure 1.8 Surveillance, diagnosis and treatment of FAP 
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FAP carriers are identified either through linkage analysis and/or genetic testing (direct 
mutation analysis) once they reach the age of around 12, or through COL investigations 
undertaken due to symptomatic presentation (see Pathway A). FAP patients in whom 
malignant colorectal tumours are not found are offered ongoing annual FSIG surveillance 
between the ages of 13-15 years. It is recommended that at the age of about 20 years, COL 
surveillance should be started, alternating between FSIG and COL thereafter. FAP carriers 
without a diagnosis of colorectal cancer may be offered prophylactic surgery at an early age. 
If cancer is found via surveillance endoscopy, the patient would undergo a CT scan of their 
chest, abdomen and pelvis or an abdominal US with a normal CXR. If the neoplasia is rectal, 
the patient will undergo an MRI scan. Upon a confirmed diagnosis of cancer, the patient will 
receive a haemoglobin test, a CEA test and treatment options will be discussed at an MDT 
meeting. Surgical options include: 
(1). Surgical removal of the bowel and rectum via proctocolectomy plus ileoanal pouch 
(IAP) followed by duodenal surveillance via oesophagogastroduodenoscopy (OGD) 
(6-monthly to 3-yearly depending on the severity of duodenal polyposis); 
(2). Surgical removal of the bowel via colectomy plus ileorectal anastomosis (IRA) 
followed by surveillance of the rectum using FSIG and duodenal surveillance via 
OGD (again 6-monthly to 3-yearly depending on severity of duodenal polyposis). 
 
The choice of surgery is driven by: 
 Patient preference with respect to saving bowel and related functioning; 
 The location of polyps - relative rectal sparing, lower risk of rectal cancer before 50 
years but higher risk of infertility with rectal excision and pouch versus colectomy 
and IRA; 
 The location of the cancer if present. 
Following colectomy and IRA, polyp surveillance using rigid sigmoidoscopy or FSIG 
continues 6-12 monthly; identified polyps are controllable with argon plasma coagulation or 
snare polypectomy or fulguration (tissue destruction) by diathermy. The presence of a high 
polyp load which is not amenable to polypectomy, or the presence of rectal cancer, are 
indications for proctocolectomy and pouch or proctectomy and ileostomy. If further polyps or 
dysplasia are found after the primary surgery, the patient may have their rectum surgically 
removed and have an IAP as described above. Treatment of patients in whom cancer is 
identified is essentially the same as that for sporadic colorectal cancers in terms of resection, 
chemotherapy, and follow-up (see Pathways B and C). The patient would also subsequently 
undergo OGD surveillance as described above. If duodenal cancer is detected via OGD 
surveillance and the patient is sufficiently fit, the patient may be considered for Whipple’s 
procedure (pancreaticoduodenectomy), which involves resecting the head of the pancreas, the 
duodenum and the bile duct (this is rare). If the patient is unfit for further surgery, they may 
be offered palliative/supportive care. Abdominal surgery may be prevented by the 
development of desmoid disease which usually presents as intestinal obstruction or a palpable 
abdominal mass; in such instances, palliative chemotherapy may be useful. 
 
1.4.8 Pathway H Surveillance, diagnosis and treatment of Hereditary Non-Polyposis 
Colorectal Cancer 
Typical pathways for the surveillance and management of HNPCC are presented in Figure 
1.9. 
 
Figure 1.9 Surveillance, diagnosis and treatment of HNPCC 
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As with FAP, HNPCC patients may be identified either through family history or through 
symptom-driven COL. Clinical genetics input is essential. Patients begin surveillance via 
COL every 2 years at the age of 25 or at 5 years younger than the youngest HNPCC affected 
relative (whichever is earlier). Surveillance continues until either: the patient reaches age 75, 
or until the causative mutation in that family has been excluded. Patients with probable cancer 
undergo a CT scan of their chest, abdomen and pelvis or an abdominal US with a normal 
CXR. If the neoplasia is in the rectum the patient will undergo an MRI scan. Upon a 
confirmed diagnosis of cancer, the patient will also have a CEA test and treatment options 
will be discussed within an MDT setting. Following a confirmed diagnosis of CRC, or 
prophylactically, patients with HNPCC are offered: 
(1) Surgical removal of their bowel and rectum via proctocolectomy plus IAP; 
(2) Surgical removal of bowel via colectomy plus IRA followed by surveillance of the 
rectum using FSIG at 1-3 yearly intervals. This option is more usual than 
proctocolectomy. 
 
As with FAP, the choice of surgery is driven by patient preferences and tumour location. If 
further polyps or dysplasia are found in patients who have had a colectomy and ileorectal 
anastomosis, the patient will have their rectum excised and will have an IAP or permanent 
ileostomy as described above. As with FAP, HNPCC patients may also be offered OGD 
surveillance. The remaining treatment pathway is similar to that for sporadic cancer. 
 
1.4.9 Pathway I Surveillance of long-standing ulcerative colitis/Crohn’s surveillance groups 
Figure 1.10 presents typical surveillance pathways for individuals diagnosed with 
UC/Crohn’s disease. These patients are managed via their GP and gastroenterologists (seen 
for diagnosis of UC/Crohn’s). Patients are offered regular COL surveillance at intervals of 1-
3 years depending on time since initial diagnosis of UC/Crohn’s: 
 annual COL for patients who have had UC/Crohn’s between 30/40 years; 
 2-yearly COL for patients who have had UC/Crohn’s between 20/30 years; 
 3-yearly COL for patients who have had UC/Crohn’s between 10/20 years. 
 
Figure 1.10 Surveillance of long-standing ulcerative colitis/Crohn’s disease  
 
The finding of colorectal cancer, severe dysplasia or dysplasia associated lesion or mass 
(DALM) is an indication for proctocolectomy and IAP or permanent ileostomy. Pouch 
patients will need ongoing pouchoscopy and biopsy on a long-term annual basis. 
Time since
diagnosis Positive population screening
Baseline Diagnosis of Positive findings
UC/Crohn's Positive symptomatic 
presentation 
Negative findings at any time
10 years 3-yearly COL Positive findings
surveillance
Cancer detected Standard colorectal cancer 
Negative findings through UC/Crohn's pathway for diagnosis
surveillance treatment and follow-up
20 years 2-yearly COL Positive findings
surveillance
Negative findings
30 years annual COL Positive findings
surveillance
Discussion 
This paper has set out a series of descriptive conceptual models of colorectal cancer and its 
detection, diagnosis, management and follow-up. The conceptual models presented here have 
been drawn from a number of evidence sources including clinical guidelines and a substantial 
amount of expert opinion. It is important to recognise that clinical guidelines prescribe how 
certain aspects of a clinical system should be delivered nationally, whilst expert opinion is 
likely to reflect how the system is delivered locally. For certain aspects of the service, for 
example, diagnostics and follow-up following treatment with curative intent, the two evidence 
sources may conflict due to geographical variation. In particular this may be driven by local 
protocols, historical service provision, the current availability of resources, and local 
enthusiasms. Given this tension, the colorectal cancer service described in this paper 
inevitably reflects a mix of what should happen in principle and what does happen in practice. 
Further, the diffusion of ongoing research into day-to-day medicine means that the colorectal 
cancer service has evolved over time and will continue to do so in the future. These issues 
should be borne in mind when considering the content of this paper. Despite these concerns, it 
is anticipated that explicitly setting out our current understanding of the disease and its 
management may lead to greater consistency in health economic models of colorectal cancer, 
and ultimately the decisions arising from their use. 
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